HDAC Inhibitors as Antifibrotic Drugs in Cardiac and Pulmonary Fibrosis

Therapeutic Advances in Chronic Disease - United States
doi 10.1177/2040622319862697
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

SAGE Publications

Related search

Idiopathic Pulmonary Fibrosis (IPF) ― Common Practice in Poland Before the “Antifibrotic Drugs Era”

Advances in Respiratory Medicine
PulmonaryRespiratory Medicine
2017English

HDAC Inhibitors in Experimental Liver and Kidney Fibrosis

Fibrogenesis and Tissue Repair
DermatologyMedicineHepatologyRheumatologyGastroenterology
2013English

FRI0461 Efficacy and Safety of Antifibrotic Agents in Idiopathic Pulmonary Fibrosis

2018English

Emerging Drugs for Idiopathic Pulmonary Fibrosis

Expert Opinion on Emerging Drugs
Pharmacology
2011English

Impact of Novel Antifibrotic Therapy on Patient Outcomes in Idiopathic Pulmonary Fibrosis: Patient Selection and Perspectives

Patient Related Outcome Measures
2018English

Pretreatment With G-CSF Could Enhance the Antifibrotic Effect of BM-MSCs on Pulmonary Fibrosis

Stem Cells International
Cell BiologyMolecular Biology
2019English

HDAC Inhibitors Show Benefits in Breast Cancer

Cancer Discovery
Oncology
2011English

Comparison of HDAC Inhibitors in Clinical Development

Human Vaccines and Immunotherapeutics
MedicineAllergyImmunologyPharmacology
2013English

Mucins as a New Frontier in Pulmonary Fibrosis

Journal of Clinical Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy